Andres Y. Analyst PerformanceSenior Biotechnology Analyst at HC WainwrightAndres Y. is a stock analyst at HC Wainwright focused in the medical sector, covering 21 publicly traded companies. Over the past year, Andres Y. has issued 45 stock ratings, including strong buy, buy, and hold recommendations. While full access to Andres Y.'s proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Andres Y.'s coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings45 Last 0 YearsBuy Recommendations95.56% 43 Buy RatingsCompanies Covered21 Unique Companies Ratings Distribution45RatingsDistribution of strong buy, buy, hold, and sell ratings by Andres Y..RatingPercentageCount Strong Buy2.2%1 ratings Buy93.3%42 ratings Hold4.4%2 ratings Sell0.0%0 ratingsOut of 45 total stock ratings issued by Andres Y. at HC Wainwright, the majority (93.3%) have been Buy recommendations, followed by 4.4% Hold and 2.2% Strong Buy.Best & Worst CallsThis analyst does not have any ratings with enough history to determine best and worst calls.Exchange CoverageExchangePercentageCountNASDAQ100.0% of companies on NASDAQ21 companiesAndres Y., an analyst at HC Wainwright, currently covers 21 companies listed on , with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical20 companies95.2%Manufacturing1 company4.8%Andres Y. of HC Wainwright specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE18 companies85.7%MED - DRUGS2 companies9.5%Miscellaneous1 company4.8% Andres Y.'s Ratings History at HC Wainwright Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsIMNMImmunome5/13/2026Reiterated Rating$22.69$40.00Buy$0.0000.00% ROIENGNenGene5/8/2026Lower Price Target$1.72$6.00Buy$0.0000.00% ROIVSTMVerastem4/10/2026Reiterated Rating$5.38$18.00Buy$0.0000.00% ROINBPI-Mab4/8/2026Reiterated Rating$2.48$9.00Buy$0.0000.00% ROICGONCG Oncology4/7/2026Boost Price Target$67.55$100.00Buy$0.0000.00% ROIAURAAura Biosciences3/30/2026Reiterated Rating$6.31$22.00Buy$0.0000.00% ROISTROSutro Biopharma3/24/2026Upgrade$21.33$28.00Buy$0.0000.00% ROINBPI-Mab3/16/2026Reiterated Rating$2.85$9.00Buy$0.0000.00% ROIERASErasca3/13/2026Boost Price Target$14.65$20.00Buy$0.0000.00% ROIFHTXFoghorn Therapeutics3/10/2026Reiterated Rating$5.48$13.00Buy$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. DAWNDay One Biopharmaceuticals3/10/2026Reiterated Rating$21.33$21.50Neutral$0.0000.00% ROIENGNenGene3/9/2026Reiterated Rating$7.38$25.00Buy$0.0000.00% ROISRRKScholar Rock3/3/2026Reiterated Rating$45.83$58.00Buy$0.0000.00% ROICGONCG Oncology2/27/2026Boost Price Target$59.09$80.00Buy$0.0000.00% ROIDAWNDay One Biopharmaceuticals2/25/2026Lower Price Target$12.02$22.00Buy$0.0000.00% ROIIBRXImmunityBio2/23/2026Boost Price Target$9.81$15.00Buy$0.0000.00% ROIIMNMImmunome2/12/2026Initiated Coverage$22.44$40.00Buy$0.0000.00% ROITARAProtara Therapeutics2/10/2026Reiterated Rating$6.48$23.00Buy$0.0000.00% ROISRRKScholar Rock1/26/2026Boost Price Target$44.29$58.00Buy$0.0000.00% ROIERASErasca1/26/2026Boost Price Target$9.96$15.00Buy$0.0000.00% ROIIBRXImmunityBio1/26/2026Boost Price Target$6.45$10.00Buy$0.0000.00% ROIERASErasca1/13/2026Boost Price Target$6.23$11.00Buy$0.0000.00% ROISTROSutro Biopharma12/22/2025Boost Price Target$9.98$10.00Neutral$0.0000.00% ROITERNTerns Pharmaceuticals12/9/2025Boost Price Target$40.23$60.00Buy$0.0000.00% ROIENGNenGene12/3/2025Reiterated Rating$7.86$25.00Buy$0.0000.00% ROITARAProtara Therapeutics12/3/2025Reiterated Rating$6.71$23.00Buy$0.0000.00% ROIDAWNDay One Biopharmaceuticals11/24/2025Reiterated Rating$9.03$25.00Buy$0.0000.00% ROITARAProtara Therapeutics11/19/2025Reiterated Rating$6.21$23.00Buy$0.0000.00% ROITCRXTScan Therapeutics11/13/2025Lower Price Target$1.19$7.00Buy$0.0000.00% ROITERNTerns Pharmaceuticals11/4/2025Upgrade$14.03$20.00Buy$0.0000.00% ROIIMABI-Mab10/27/2025Reiterated Rating$4.53$7.00Buy$0.0000.00% ROISNDXSyndax Pharmaceuticals10/27/2025Reiterated Rating$13.53$40.00Buy$0.0000.00% ROICRBPCorbus Pharmaceuticals10/20/2025Reiterated Rating$19.32$40.00Buy$0.0000.00% ROISNDXSyndax Pharmaceuticals10/16/2025Initiated Coverage$15.04$40.00Buy$0.0000.00% ROISNDXSyndax Pharmaceuticals10/15/2025Upgrade$15.05Strong-Buy$0.0000.00% ROIMNPRMonopar Therapeutics9/29/2025Set Price Target$76.63$105.00Buy$0.0000.00% ROICADLCandel Therapeutics9/29/2025Reiterated Rating$5.38$23.00Buy$0.0000.00% ROISRRKScholar Rock9/23/2025Lower Price Target$32.37$44.00Buy$0.0000.00% ROICRBPCorbus Pharmaceuticals9/17/2025Reiterated Rating$10.27$40.00Buy$0.0000.00% ROICGONCG Oncology9/15/2025Reiterated Rating$33.34$75.00Buy$0.0000.00% ROIRead this or regret it forever (Ad)Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” Porter Stansberry exposes how the convergence of three immense forces is about to rewrite everything about the American way of life: how you work, save, invest… it’s all about to change.Don’t be left behind. Click here now.IBRXImmunityBio9/10/2025Reiterated Rating$2.57$8.00Buy$0.0000.00% ROIENGNenGene9/8/2025Reiterated Rating$5.18$25.00Buy$0.0000.00% ROICGONCG Oncology9/5/2025Reiterated Rating$32.52$75.00Buy$0.0000.00% ROIAURAAura Biosciences8/13/2025Reiterated Rating$7.21$22.00Buy$0.0000.00% ROIKROSKeros Therapeutics8/8/2025Lower Price Target$13.36$20.00Buy$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageUBS GroupCitigroupBarclaysWells Fargo & CompanyMorgan StanleyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerStifel NicolausRaymond James FinancialBMO Capital Markets Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
